Articles of the Month
Videos
Articles
Algorithms in Allergy: Diagnosis of Hypereosinophilic Syndromes, 2026 Update
G.Lefèvre, F.Roufosse, G.Emmi, et al.Allergy. First published:08 October 2026
Natural Diversity of Grass Pollen in Europe—An EAACI Perspective
L.Klimek, M.J.Torres, J.Bousquet, et al.Allergy. First published:08 October 2026
Butyrate Modulates CXCR4 Expression and IL‐5‐Induced Inflammatory Responses in Human Eosinophils
E.Matsuyama, J.Miyata, Y.Kawashima, et al.Allergy. First published:08 October 2026
Exploring the Link Between Environmental Exposures and Disease via Direct Challenge
A.M.Erickson, I.A.Myles, J.L.Blake, et al.Allergy. First published:07 October 2026
Algorithms in Allergy: Treatment of Hypereosinophilic Syndromes, 2026 Update
G.Lefèvre, F.Roufosse, G.Emmi, et al.Allergy. First published:06 October 2026
Selective Absence of Co-Inhibitory Receptor-Expressing CD4+ T Cells in Lungs of Obese House Dust Mite-Allergic C57BL/6 Mice
S.Miethe, D.P.Potaczek, K.Pauck, et al.Allergy. First published:04 October 2026
Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy
M.Simard, C.Braun, &.Antony, et al.Allergy. First published:30 September 2026
Co-Sensitization, Reactivity and Severity: Three Distinct Layers of Vicilin-Based Diagnosis
B.E. Şekerel, Ö.Soyer, M.Ocak.Allergy. First published:27 September 2026
Diagnostic Delay in Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors and Implications for Earlier Recognition
V.Mulkareddy, K.Liu, S.Mandloi, et al.Allergy. First published:27 September 2026
Molecular Heterogeneity in Clinically Ambiguous Atopic Dermatitis–Psoriasis Overlap: Compartment-Resolved Transcriptomic Profiling
J.Lee, Y.S.Chun, H.J.Nam, et al.Allergy. First published:25 September 2026
The EAACI Declaration of Salamanca: A European Roadmap for Strengthening Undergraduate Medical Education in Allergy and Clinical Immunology
M.J.Torres, M.H.Shamji, S.Arasi, et al.Allergy. First published:23 September 2026
Stool and Airway Microbiome Signatures Associated With Treatment Response to Dupilumab in Severe Asthma: Findings From the PRISM Study
G.Yie, E.Kim, D.D.Pham, et al.Allergy. First published:22 September 2026
Increased CEA Expression in Nasal Polyps Is Associated With Plasma Cell Infiltration
J.Y.Han, M.H.Tabor, L.E.Ryan, et al.Allergy. First published:20 September 2026
IgE-Binding Bacterial Components Not Yet Documented in the Allergen Databases and Their Allergenic Mechanisms: An EAACI Position Paper
U.Jappe, M.A.Risha, I.Agache, et al.Allergy. First published:18 September 2026
Legends of Allergy and Immunology: Johannes Ring
C.Traidl-Hoffmann.Allergy. First published:18 September 2026
IgE Sensitization Patterns of Mothers and Their Offspring in the First Five Years of Life The CHILD Study
M.A.A.Kodydek, M.E.Reyna, A.Kothari, et al.Allergy. First published:16 September 2026
Single-Cell Profiling Links T-Cell Accumulation and TH2/TH17 Dynamics to Eosinophilic Esophagitis (EoE) Activity in Children
H.Hoelz, M.T.Warkotsch, S.Buehler, et al.Allergy. First published:15 September 2026
Algorithms in Allergy: Practical Approaches to Drug Desensitisation
R. Madrigal-Burgaleta, P. Vazquez-Revuelta, A. Guzman-Melendez, and E. Alvarez-Cuesta. Allergy. First published:15 September 2026
Cumulative Vulnerability to Particulate Matter and Incident Asthma: Joint Effects of Urbanicity, Poverty, and Age in a Nationwide Cohort
H.Lee, J.Heo, J.Nam, et al.Allergy. First published:11 September 2026
Citations: 342
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766
Citations: 147
EAACI guidelines: Anaphylaxis (2021 update)
Muraro A, Worm M, Alviani C, et al. Allergy. 2022; 77: 357–377
Citations: 118
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
Maurer M, Magerl M, Betschel S, et al. Allergy. 2022; 77: 1961–1990
Citations: 118
The role of peripheral blood eosinophil counts in COVID-19 patients
Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482
Citations: 114
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease
Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Allergy. 2022; 77: 1418–1449
Citations: 105
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice
Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432
Citations: 92
Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation
Klimek, L., Novak, N., Cabanillas, B., et al. Allergy. 2021; 76: 3307-3313
Citations: 90
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines
Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639
Citations: 88/h5>
The role of allergen-specific IgE, IgG and IgA in allergic disease
Shamji MH, Valenta R, Jardetzky T, et al. Allergy. 2021; 76: 3627–3641
Citations: 82
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676
Citations: 81
Advances and highlights in allergic rhinitis
Zhang Y, Lan F, Zhang L. Allergy. 2021; 76: 3383–3389
Citations: 79
Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618
Citations: 76
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353
Citations: 74
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Citations: 73
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches
Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Allergy. 2022; 77: 812–826
Citations: 70
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., et al. Allergy. 2021; 76: 1640-1660
Citations: 69
Advances and highlights in biomarkers of allergic diseases
Ogulur I, Pat Y, Ardicli O, et al. Allergy. 2021; 76: 3659–3686
Citations: 69
Regulatory B cells, A to Z
Jansen, K., Cevhertas, L., Ma, S., Satitsuksanoa, P., Akdis, M. and van de Veen, W.
Citations: 62
Advances and highlights in asthma in 2021
Agache I, Eguiluz-Gracia I, Cojanu C, et al. Allergy. 2021; 76: 3390–3407
Citations: 62
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Citations: 61
The ingenious mast cell: Contemporary insights into mast cell behavior and function
Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 2022; 77: 83-99
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, et al. Allergy. 2022; 77: 734– 766
The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414
Risk factors for severe and critically ill COVID-19 patients: A review
Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455
Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741
Advances and recent developments in asthma in 2020
Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022
A compendium answering 150 questions on COVID-19 and SARS-CoV-2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541
Special Issue: Perspectives in Allergen Immunotherapy: 2019 and Beyond
Volume 74 | Issue S108
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review
Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016
Eczema herpeticum in atopic dermatitis
Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027
CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers
McKenzie, C.I., Varese, N., Aui, P.M., et al. Allergy. 2021; 76: 3028-3040
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study
Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052
Direct assessment of individual skin barrier components by electrical impedance spectroscopy
Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106
Prenatal paraben exposure and atopic dermatitis-related outcomes among children
Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132
Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis
Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154
Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy
Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196
Transgenic mice overexpressing the PGE2 receptor EP2 on mast cells exhibit a protective phenotype in a model of allergic asthma
Urbano, A., Plaza, J., Turon, S., et al. Allergy. 2021; 76: 3196-3199
Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma
Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202
Identification of Ulocladium chartarum as an important indoor allergen source
Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206
Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis
Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Remington, B.C., Koppelman, S.J., Green, T.D., et al. Allergy. 2021; 76: 3223-3226
Legends of allergy and immunology: Sergio Bonini
Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229
Medical algorithm: Peri-operative management of mastocytosis patients
Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235
Open Access Agreements with Wiley
Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley
Junior Members Corner
Dear Juniors,
EAACI Congress 2026 in Istanbul once again provided an outstanding opportunity for Junior Members to engage with the latest advances in allergy and clinical immunology while connecting with colleagues from across Europe and beyond. Bringing together clinicians, scientists and healthcare professionals from a wide range of disciplines, the congress fostered an inspiring environment for scientific exchange, collaboration and professional development.
For many Junior Members, the congress represented far more than attending lectures. It offered the opportunity to present research, discuss new ideas with internationally recognised experts, receive valuable feedback and build collaborations with peers from different institutions and countries. Dedicated sessions organised by the Junior Member Assembly (JMA) encouraged lively discussions on emerging topics across the specialty, providing an interactive platform for learning, exchanging experiences and showcasing the high-quality research being conducted by Junior Members.
Alongside the scientific programme, the JMA supported a range of educational and networking initiatives designed to promote the professional development of early-career members. Activities such as the EAACI Allergy College, the Clinical Research Challenge and the Junior Members Mentorship Programme created opportunities to strengthen mentoring relationships, develop new skills and establish international connections that often continue well beyond the congress itself. Together, these initiatives reflect EAACI’s continued commitment to supporting the next generation of allergy and clinical immunology professionals.
Perhaps the greatest strength of the EAACI Congress is the sense of community it creates. Whether attending for the first time or returning as experienced participants, Junior Members have the opportunity to become part of a collaborative international network united by a shared passion for research, education and improving patient care. We look forward to welcoming even more Junior Members to future EAACI meetings and encourage you to make the most of the many opportunities the JMA and the wider Academy provide throughout the year.
Best regards,
The Junior Member Assembly
EAACI Patients Organisation Committee Corner
HIGHLIGHTS FROM PAAM 2025
A group of ten Patient Organisations Committee (POC) members gathered at this wonderful venue in Palau de Congressos de Palma, Mallorca for 2025 Pediatric Allergy and Asthma Focused Meeting. Many had speaker slots giving lived experience perspectives of having children living with allergy and risk of anaphylaxis. So the EAACI PAAM Congress theme of ‘Inspiring insights for every family’ really resonated with us.
As POC, we are with EAACI to help where we can and it brings the science to a person experience, centred level. We had members a wide range of participants from Chile, USA, Turkey, UK, Sweden, Switzerland, France, Italy, Greece and Spain as POC has 36 POC members in 24 countries.
Our Chair, Ozlem Ceylan, gave an overview at the Opening Ceremony on why EAACI awareness campaigns matter, from awareness to action, so patients can feel heard and patient organisations can help lobby for policy change in their country.
POC participated in the Student Awareness Day that was set to educate 40 students aged 14-16 about allergic diseases and emergency response, with the local organising committee’s support.
One of our POC members, Esther Esteban Arroyo opened “The sister society session” with SEICAP and introduced their patient organisation, AEPNAA and their activities in Spain.
Mikaela Odemyr from Swedish Asthma and Allergy Association joined the Anaphylaxis session with a heartfelt talk, “When My Child Had Anaphylaxis: Expectations vs. Reality”. Fallon Schultz from IFPIES USA, gave a wonderful talk on parents’ perspective of dealing with a child’s FPIES journey and introduced their resources to support caregivers. On the last day of PAAM, Maria Zioga from Greece, gave a great talk, “From panic to preparedness: Building trust and resilience in food allergy care” and highlighted the importance of safety for food allergic children.
GA Gallery
<---
